Insulin glargine biosimilar - GEROPHARM

Drug Profile

Insulin glargine biosimilar - GEROPHARM

Latest Information Update: 19 Dec 2015

Price : $50

At a glance

  • Originator GEROPHARM
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Dec 2015 Clinical trials in Type-1 diabetes mellitus in Russia (SC) prior to December 2015 (GEROPHARM pipeline, December 2015)
  • 19 Dec 2015 Clinical trials in Type-2 diabetes mellitus in Russia (SC) prior to December 2015 (GEROPHARM pipeline, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top